OncoMatch/Clinical Trials/NCT06914037
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Is NCT06914037 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CHT101 for peripheral t-cell lymphoma.
Treatment: CHT101 — Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD70 positive (positive)
Disease stage
Required: Stage IIB AND ABOVE (FOR CTCL)
stage ≥IIB with disease involving two or more compartments or single-compartment disease with large-cell transformation (for CTCL); measurable disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
Peripheral T cell lymphoma...who have failed ≥1 line of systemic therapy
Must have received: systemic therapy
Cutaneous T cell lymphoma...who have failed ≥2 lines of systemic therapies
Must have received: systemic therapy containing anti-CD20 antibody and anthracyclines
Aggressive B cell lymphoma who are refractory or relapsed post ≥2 lines of systemic therapies which contain anti-CD20 antibody and anthracyclines
Must have received: systemic therapy containing anti-CD20 antibody
Indolent B cell lymphoma who are refractory or relapsed post ≥2 lines of systemic therapies which contain anti-CD20 antibody
Must have received: systemic therapy containing BTK inhibitor and BCL-2 inhibitor
Chronic lymphocytic leukemia (CLL) who are refractory or relapsed post ≥2 lines of systemic therapies which contain BTK inhibitor and BCL-2 inhibitor
Cannot have received: CD70-targeting agent
Prior treatment with CD70-targeting agents
Cannot have received: CAR-T cell therapy
Prior treatment with CAR-T or other cellular/gene therapies
Cannot have received: cellular/gene therapy
Prior treatment with CAR-T or other cellular/gene therapies
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify